MRI of the breast has the highest sensitivity for breast cancer detection among current
clinical imaging modalities and is indispensable for breast imaging practice. While the basis …

Multiple studies in the first decade of the 21st century have established contrast‐enhanced
breast MRI as a screening modality for women with a hereditary or familial increased risk for …

The therapeutic options for patients with noninvasive or invasive breast cancer are complex
and varied. These NCCN Clinical Practice Guidelines for Breast Cancer include …

Ductal carcinoma in situ (DCIS) of the breast represents a heterogeneous group of
neoplastic lesions in the breast ducts. The goal for management of DCIS is to prevent the …

In 1988, the first contrast agent specifically designed for magnetic resonance imaging (MRI),
gadopentetate dimeglumine (Magnevist®), became available for clinical use. Since then, a …

Purpose We investigated whether an abbreviated protocol (AP), consisting of only one pre-
and one postcontrast acquisition and their derived images (first postcontrast subtracted …

This paper summarizes information about breast MRI to be provided to women and referring
physicians. After listing contraindications, procedure details are described, stressing the …

Ultrasound imaging is a commonly used modality for breast cancer detection and diagnosis.
In this review, we summarize ultrasound imaging technologies and their clinical applications …

Ductal carcinoma in situ (DCIS) is a nonobligate precursor of invasive cancer, and its
detection, diagnosis, and management are controversial. DCIS incidence grew with the …

Background The current debate on overdiagnosis and overtreatment of screen-detected
ductal carcinoma in situ (DCIS) urges the need for prospective studies to address this issue …